XNAS
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | Q1 2026 | — | -3.74 | -11.90% | $3.7M | — | +0.74% | +0.44% | -1.62% |
| 2026-03-16 | Q4 2025 | -3.89 | -3.61 | +7.20% | $1.3M | ✅ Beat | +0.00% | +0.86% | +1.71% |
Showing last 2 quarters.